NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery | NVIDIA Newsroom

NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery

June 23, 2026

News Summary:

Industry and research leaders including Dassault Systèmes, Databricks, Lilly, Schrödinger, Snowflake, the UW Medicine Institute for Protein Design and dozens others are adopting, and Anthropic and OpenAI are integrating, NVIDIA BioNeMo Agent Toolkit to bring agentic life sciences workflows to researchers and scientists.

NVIDIA BioNeMo Agent Toolkit — including NVIDIA Nemotron, NemoClaw, OpenShell and BioNeMo — gives agents accelerated life sciences tools spanning biology, chemistry, genomics and drug discovery.

New NVIDIA BioNeMo tools give agents the context and know-how to execute scientific computing — improving accuracy, task completion and token efficiency.

BIO —NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era.

Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery.

It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions.

The toolkit includes NVIDIA BioNeMo™ and is powered by NVIDIA NIM™ microservices, NVIDIA Parabricks®, NVIDIA NeMo™ and NVIDIA Nemotron™ technologies, along with accelerated computing and skills — providing an open and trusted foundation for agentic life sciences.

More than 50 leading companies are already using it to advance scientific discovery, tapping into agent-callable skills for tasks including protein structure prediction, molecular docking, generative chemistry, genomic analysis, protein design and biomarker discovery.

“Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer,” said Jensen Huang, founder and CEO of NVIDIA. “For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science — one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine.”

Open model and research organizations — including the Arc Institute, Open Molecular Software Foundation and the University of Washington’s Institute for Protein Design (IPD) — are working with NVIDIA to use BioNeMo to advance frontier models and make them more accessible through agent-ready workflows. The IPD collaboration has accelerated runtimes for state-of-the-art biodesign models like RosettaFold3, resulting in 2x faster performance than the prior-generation model, and many additional applications to accelerate protein design efforts are ongoing, giving researchers tools at a scale and cost not before possible.

“Every tool we’ve built for protein design is only as powerful as the scientists who can efficiently access it,” said David Baker, professor of biochemistry at the University of Washington School of Medicine and director of the Institute for Protein Design. “The next leap in science won’t come from a single discovery; it will come from the speed of iterative designs and agents that can repeatedly reason through the complexity of biology at a speed humans never could.”

Agent-Ready Tools and Skills for Life Sciences

Life sciences is one of the world’s most important scientific frontiers, with global scientific R&D reaching $3.8 trillion and annual pharmaceutical budgets approaching $300 billion.

Agentic workflows can help the industry iterate faster while reducing costs and maximizing the probability of success. With the toolkit allowing developers to transform general-purpose agents into life sciences agents in minutes, researchers can run experiments faster, continuously learn from results and close the loop between hypothesis and discovery, with some companies extending this iteration into physical labs.

A general-purpose agent can struggle to navigate scientific workflows efficiently, needing to infer the correct tools, inputs, outputs and biological meaning along the way. With BioNeMo Agent Toolkit, agents can call the right tools, interpret results more accurately and gain scientific insights faster and more reliably.

NVIDIA is optimizing the entire BioNeMo platform by turning libraries, models and frameworks into agent-callable...